Literature DB >> 9583767

The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression.

F Benedetti1, M Amanzio, S Baldi, C Casadio, A Cavallo, M Mancuso, E Ruffini, A Oliaro, G Maggi.   

Abstract

Although in most of the cases the placebo response appears to be unpredictable, several factors have been considered in order to explain the placebo analgesic effect. For example, it is widely recognized, albeit with little empirical evidence, that placebo analgesia is more likely to occur after a successful analgesic therapy. On the basis of this assumption, we tested the placebo response in a population of patients who were treated with buprenorphine the day before for relieving postoperative pain. However, due to the high variability of opioid responsiveness, buprenorphine was effective in some patients and poorly effective in some others. Similarly, buprenorphine produced respiratory depression with a large variability, ranging from mild depression to no effect. We found that the placebo analgesic response depended on the buprenorphine analgesic effectiveness of the previous day. Analogously, we found that a placebo respiratory depressant response was more pronounced in those patients with a respiratory depressant response to buprenorphine on the day before, irrespective of the analgesic effectiveness. These specific effects suggest that (1) the placebo effect is experience-dependent; (2) the mechanisms underlying placebo analgesia and placebo respiratory depression are independent from each other and, by considering the role of endogenous opioids in placebo analgesia, might involve different subpopulations of opioid receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583767     DOI: 10.1016/s0304-3959(98)00010-4

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  12 in total

1.  Placebo Analgesia - Understanding the Mechanisms and Implications for Clinical Practice.

Authors:  Damien G Finniss; Michael K Nicholas; Fabrizio Benedetti
Journal:  Rev Pain       Date:  2009-10

Review 2.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

3.  Somatotopic activation of opioid systems by target-directed expectations of analgesia.

Authors:  F Benedetti; C Arduino; M Amanzio
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

Review 4.  The neuroscience of placebo effects: connecting context, learning and health.

Authors:  Tor D Wager; Lauren Y Atlas
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

Review 5.  Placebo interventions for all clinical conditions.

Authors:  Asbjørn Hróbjartsson; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

6.  Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems.

Authors:  M Amanzio; F Benedetti
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

7.  Expectations and placebo responses to caffeine-associated stimuli.

Authors:  Magne Arve Flaten; Ole Aasli; Terry D Blumenthal
Journal:  Psychopharmacology (Berl)       Date:  2003-05-21       Impact factor: 4.530

Review 8.  Placebo and the new physiology of the doctor-patient relationship.

Authors:  Fabrizio Benedetti
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

9.  Handling Ibuprofen increases pain tolerance and decreases perceived pain intensity in a cold pressor test.

Authors:  Abraham M Rutchick; Michael L Slepian
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  Placebo use in the United kingdom: results from a national survey of primary care practitioners.

Authors:  Jeremy Howick; Felicity L Bishop; Carl Heneghan; Jane Wolstenholme; Sarah Stevens; F D Richard Hobbs; George Lewith
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.